AbbVie Stock Surges on Analyst Optimism Amid Pharmaceutical Sector Volatility
AbbVie shares rallied more than 3% Friday, defying a 1.6% sector downturn, after multiple analysts raised price targets following strong Q2 results. The bullish revisions—including Morgan Stanley's $255 target and Guggenheim's $227 valuation—highlight confidence in blockbuster drugs like Skyrizi driving growth.
Market sentiment strengthened as three major firms maintained buy ratings despite modest target increases. The stock's outperformance underscores how pharmaceutical equities can decouple from broader market trends when demonstrating commercial execution.